Bristol Myers to pay $1.5 billion upfront for BioNTech cancer drug partnership
June 2 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab will pay $1.5 billion upfront to partner with Germany's BioNTech (22UAy.DE), opens new tab, on an experimental cancer drug, the U.S. company said on Monday, in a deal that could eventually exceed $11 billion in value for BioNTech.
Bristol said it will co-develop and co-commercialize BioNTech's drug, BNT327, for multiple solid tumour types.
The deal underscores the industry's focus on a new dual mechanism of action in oncology. BNT327 is designed to activate the immune system, similar to an established drug class including Merck & Co's (MRK.N), opens new tab Keytruda, but also to cut a tumour's blood supply.
"We are impressed by the innovation that BioNTech has achieved to date and we look forward to partnering to accelerate existing clinical trials and time to market, while expanding the number of potential indications," Bristol Myers CEO Chris Boerner said in a statement.
Instil Bio, opens new tab(TIL.O), opens new tab and ImmuneOnco (1541.HK), opens new tab are working on a similar compound called SYN-2510. Summit Therapeutics, opens new tab(SMMT.O), opens new tab and Akeso (9926.HK), opens new tab have formed another partnership in the development race with a drug candidate called ivonescimab.
BioNTech took full ownership of BNT327 through the acquisition, opens new tab of China's Biotheus earlier this year for $800 million upfront and up to $150 million contingent on development achievements.
It previously held certain rights in the drug under a 2023 collaboration, opens new tab deal.
In addition to the initial payment, Bristol plans to pay BioNTech up to $2 billion more in non-contingent anniversary payments through 2028. BioNTech may also earn up to $7.6 billion more in development, regulatory and commercial milestones, Bristol said.
The companies will share global profits and losses from the drug equally, and joint development and manufacturing costs will also be shared on a 50/50 basis, subject to some exceptions.
BNT327, part of a drug category known as bispecific antibodies, is currently being tested as a first-line treatment in extensive stage small cell lung cancer and non-small cell lung cancer. More than 1,000 patients have been treated with the drug to date.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
15 minutes ago
- The Sun
Man Utd odds SLASHED in Jamie Vardy next club market as Wrexham & Rangers trail
JAMIE VARDY is still on the lookout for his next challenge after quitting Leicester City. And judging by the sustained support with the bookmakers, a move to MANCHESTER UNITED is looking ever more likely by the day! 2 2 The 38-year-old has been linked with several clubs across Europe since he revealed he was quitting the Foxes. A club legend - described by Leicester as 'our greatest-ever player' - Vardy leaves having scored 200 goals in 500 appearances for the side. He also worked under 10 different managers in his 13 years at the King Power. In a lengthy statement, he closed it off by saying: "It's finally time to call it a day, which I'm devastated about it, but I think the timing it right." Vardy has been strongly linked with a move north of the border, with former boss Brendan Rodgers at Celtic before more concrete claims of interest from Rangers, who have recently been taken over. A move to Serie A is the current frontrunner with BetVictor, priced at 9/4 to move to any club. But without doubt the market mover in the Vardy next club market is for Manchester United, who were reportedly interested at the end of the January window. Ruben Amorim is desperate for options up to, with Marcus Rashford and Alejandro Garnacho on the way out and Rasmus Hojlund potentially exiting with them. Only Everton and the three, poor relegated sides scored less goals than United in the Premier League last season. They're trying to resolve that issue, having splurged over £60million on Matheus Cunha and in advanced talks with Bryan Mbeumo. So this move for Vardy on a free would be a much cheaper option to bolster the front line and likely be an attractive proposition for both parties. Such is the incredible nature of this market, Championship new boys Wrexham come next at 8/1 third favourites. The Hollywood-owned side were coined the 'obvious transfer choice of the century' for Vardy when he first revealed he was leaving Leicester but that seems to have cooled. A switch to Scotland, Crystal Palace and Sheffield Wednesday are all also 8/1. Remember to gamble responsibly A responsible gambler is someone who: For help with a gambling problem, call the National Gambling Helpline on 0808 8020 133 or go to to be excluded from all UK-regulated gambling websites.
BBC News
19 minutes ago
- BBC News
Measles warning for holidaymakers heading to Europe
Families travelling abroad this summer on holiday or to visit relatives are being warned about the rise in measles cases in Europe and other infections in Europe are at a 25-year high, while cases are also surging in countries such as Pakistan and vaccination rates in the UK that offer protection against measles, mumps and rubella (MMR) are still a long way below the recommended 95% uptake, with the lowest regional rates found in London at just over 73% UK Health Security Agency is warning holidaymakers to make sure they are up to date with their vaccinations and stress that it is never too late to get vaccinated. The UKHSA's latest data on measles infections shows that an outbreak is continuing in 109 cases were confirmed in April and 86 so far in May. These cases have mostly been in unvaccinated children aged 10 years and under. London has reported almost half of all cases in the past four Vanessa Saliba, consultant epidemiologist at the UK Health Security Agency, says the rise in cases in England reflects what is happening abroad - and that's a concern as the summer holiday season gets going. "It's essential that everyone, particularly parents of young children, check all family members are up to date with two MMR doses, especially if you are travelling this summer for holidays or visiting family," Dr Saliba said."Measles cases are picking up again in England and outbreaks are happening in Europe and many countries with close links to the UK."Measles spreads very easily and can be a nasty disease, leading to complications like ear and chest infections and inflammation of the brain with some children tragically ending up in hospital and suffering life-long consequences. "Nobody wants this for their child and it's not something you want to experience when away on holiday." European cases hit a 25-year high The decline in vaccination rates in the UK - particularly since the Covid pandemic - has been mirrored in other countries, especially in Europe. The World Health Organization and UNICEF reported 127,350 measles cases in the European Region in 2024 - double the number of cases reported during the previous year and the highest number since year has seen outbreaks in several other European countries popular with UK holidaymakers, including France, Italy, Spain and WHO has also reported that Romania, Pakistan, India, Thailand, Indonesia and Nigeria currently have among the largest number of measles cases worldwide. Never too late There has been a big push to improve MMR vaccination rates across the UK, but Dr Amanda Doyle, national director for primary care and community services at NHS England, says there is still a lot of work to do."Too many babies and young children are still not protected against the diseases, which are contagious infections that spread very easily and can cause serious health problems. "MMR jabs are provided free as part of the NHS routine immunisation programme – and I would encourage all parents to act on invites or check vaccination records if they think they may have missed their child's vaccination."Health experts say that anyone, whatever their age, who has not had two doses of the MMR vaccine can contact their GP surgery to book an appointment and that it is never too late to catch up.
The Independent
19 minutes ago
- The Independent
NHS body revokes guidance advising hospitals to allow trans people to use chosen bathrooms
An NHS body has been criticised after it quietly withdrew guidance advising hospitals to allow trans people to use bathrooms and changing rooms of their choice. The NHS Confederation - which represents NHS trusts across the UK - confirmed to The Independent that it had removed the guidance from its website as it became 'dated' after April's Supreme Court ruling. The judgment found that the terms 'woman' and 'sex' in the Equality Act refer to a biological woman and biological sex, sparking disputes on how Britain should treat its equality policy. In the weeks after the ruling, the Equality and Human Rights Commission (EHRC) issued interim guidance which stated that trans women 'should not be permitted to use the women's facilities' in workplaces or public-facing services such as shops and hospitals'. The guidance is being legally challenged by trans-rights groups. The NHS Confederation said it had withdrawn its previously trans-inclusive advice and will issue new guidance when the EHRC updates its official Code of Practice. But trans rights groups have warned guidance on access to single-sex spaces is currently a legal 'minefield'. "The Supreme Court decision about the Equality Act doesn't mention toilets - not even once - and their provision is governed by separate legislation,' founder and executive director of Good Law Project, Jo Maugham KC, told The Independent. 'What the Supreme Court was very careful to say is that its judgment about the meaning of "woman" was solely about that word in the Equality Act. The 'toilets question' will be determined in judicial review proceedings that Good Law Project is filing today. 'For the NHS (or any other service provider) to take a position before the outcome is known is to invite lawsuits against it and risk wasting money that ought to be spent on patient care in the pursuit of ill-advised culture wars." TransActual, an organisation that supports the rights of trans people, said the development highlights the confusing implications of the ruling. "This decision may - or may not - be required as a result of the recent Supreme Court ruling,' a spokesperson said. 'However, what appears abundantly clear, based on advice from multiple lawyers and experts in this field, is that the supposed 'clarity' welcomed by the prime minister shortly after the ruling is, itself, in need of some clarification. "The law, based on a narrow interpretation of the Equality Act, may support this action. Equally, any future challenges on human rights grounds, which were not considered by the Supreme Court, may lead to a different outcome. It is a minefield. Organisations are damned if they act; damned if they do not. "We sympathise with the NHS Confederation and the position they find themselves in. Nonetheless, we believe they have reached the wrong conclusion - and that will, in turn, lead to significant harm to trans people needing medical care, as they now put off, or refuse treatment that may require a hospital stay." The NHS Confederation - which does not set official NHS policy - said its intention remains to provide its members with 'information that helps them best support their staff and patients', as it confirmed it had taken its previous guidance down. A spokesperson said: 'We will update and reinstate our guide as soon as the EHRC has updated its Code of Practice, which will need to be approved by the UK government, and when NHS England has then updated its guidance for what the changes mean for NHS organisations. 'The withdrawal of our guide does not change our explicit commitment to support our members to reduce the unacceptably high levels of bullying, abuse and discrimination at work that trans and non-binary staff and patients face.' On Monday, a hearing in a case against the EHRC over its consultation period for guidance in the wake of the Supreme Court ruling is set to go ahead. Human rights group Liberty is arguing the equalities watchdog had breached its statutory duties by implementing a six-week consultation period rather than a 12-week one. The EHRC will issue official post-ruling guidance after the consultation period.
